PharmaShots | Incisive News in 3 Shots

Subscribe Now

All Posts by Date

Exclusive Interview with PharmaShots: Jeremiah Robison of Cionic Shares Insight on Neural Sleeve for Neurological Disorders

Exclusive Interview with PharmaShots: Jeremiah Robison of Cionic Shares Insight on Neural Sleeve for Neurological Disorders

March 30, 2022

Fresenius Kabi’s Stimufend (biosimilar, pegfilgrastim) Receives EC’s Approval for Oncology Indications

Fresenius Kabi’s Stimufend (biosimilar, pegfilgrastim) Receives EC’s Approval for Oncology Indications

March 30, 2022

ViiV Healthcare’s Cabenuva (cabotegravir, rilpivirine) Receives the US FDA’s Approval for Virologically Suppressed Adolescents with HIV

ViiV Healthcare’s Cabenuva (cabotegravir, rilpivirine) Receives the US FDA’s Approval for Virologically Suppressed Adolescents wit...

March 30, 2022

Pyxis Oncology In-Licenses BSI-060T From Biosion for the Treatment of Solid Tumors

Pyxis Oncology In-Licenses BSI-060T From Biosion for the Treatment of Solid Tumors

March 30, 2022

Albireo Report Enrollment Completion in P-III (ASSERT) Study of Bylvay (odevixibat) for the Treatment of Alagille Syndrome

Albireo Report Enrollment Completion in P-III (ASSERT) Study of Bylvay (odevixibat) for the Treatment of Alagille Syndrome

March 30, 2022

Antengene’s Eltanexor (ATG-016) Receive the NMPA’s IND Approval for P-II Study to Treat Patients with High-Risk Myelodysplastic Syndromes

Antengene’s Eltanexor (ATG-016) Receive the NMPA’s IND Approval for P-II Study to Treat Patients with High-Risk Myelodysplastic Sy...

March 30, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us